Getting more from multimodal omics

Unlocking the full potential of multimodal omics to get the highest return on investment.

Have you ever felt like you're not quite getting to the meaningful biological discoveries and tangible conclusions you expected to get from your multimodal omics? It's easy to get lost in the complexity and just stick to old recipes. We end up missing out on proper discovery of MoA, novel targets or combination strategies, and biomarkers for patient selection. Here is an alternative view of the discovery process, showcasing how we can unlock the full potential of multimodal omics and get the highest return on our investment.

I've been diving deep into the world of single-cell genomics over the past few years, employing a diverse arsenal of analytical and experimental strategies to enhance our understanding of anti-tumor immunity in patients. I identified novel molecular programs, decoded T cell clonality patterns, and uncovered how the spatial positioning and interaction patterns of rare immune cell subsets may drive response or resistance to immunotherapy (Magen et al. Nat Med (2023))…